Who Really Creates Value in the Economy—and Who Extracts It?

The Value of Everything: Making and Taking in the Global Economy — Mariana Mazzucato, 2018

This book challenges modern economic thinking by questioning how we define value. It argues that many activities labeled as “wealth creation” are actually value extraction, and that flawed ideas about value allow inequality, financialization, and misallocated rewards to persist across the global economy.

1. Modern economics has lost a clear theory of value

2. Historical theories of value distinguished between productive and unproductive activity

3. The shift to subjective value erased the distinction between value creation and extraction

4. GDP and national accounts reinforce flawed definitions of value

5. The financial sector has been redefined as value-creating, despite often extracting value

6. Financialization has reshaped the entire economy toward short-term gains

7. The innovation economy mixes value creation with value extraction

8. The public sector is systematically undervalued

9. Misunderstanding value leads to inequality and poor policy

10. Markets are shaped by policy, not natural forces

11. Reclaiming value theory is necessary for a fairer economy

⭐ Star Facts (The Value of Everything)

From 1975 to 2015, U.S. GDP nearly tripled, yet real wages for most workers stagnated, showing growth did not translate into broad value distribution.
The top 1% income share in the U.S. rose from 9.4% (1980) to 22.6% (2007), highlighting how gains increasingly go to a small elite.
In 2015, 62 individuals owned as much wealth as the bottom 3.5 billion people globally, demonstrating extreme concentration of economic rewards.
Financial firms like Goldman Sachs received massive bailouts (e.g., $125 billion in U.S. support) yet returned to high profits soon after, illustrating public risk and private reward.
After the 2008 crisis, banks continued generating tens of billions in profits, despite their role in the crash, showing how value extraction persists without structural change.
Pharmaceutical companies use “value-based pricing” to justify extremely high drug prices (e.g., a hepatitis C treatment priced at ~$94,500), even when public funding contributed to research.